- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07635576
Effect of Gastric Electrical Stimulation on Serum Insulin Levels
Defining the Effect of Gastric Electrical Stimulation on Serum Insulin Levels in Human Subjects
The goal of this study is to determine how much effect turning off an individual's Gastric Electrical Stimulator (GES) for up to four hours will have on levels of insulin, C-peptide, GLP-1 and glucose levels.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Up to thirty-two adult patients with gastroparesis who have undergone implantation of a gastric stimulation device at least three months prior may participate in this study, which will be completed at a single study visit.
The study consists of two groups, an EXPERIMENTAL group that undergoes turning off the GES and a CONTROL group that does not undergo the turning off of the GES. The subjects are randomized to either the control or experimental group.
After an overnight fast, consented and eligible patients are placed in the supine position on a hospital bed, and an intravenous line is inserted and capped. EKG electrodes will be placed on the chest, arms/legs, behind each ear and just under the jaw on each side to record cardiac and vagal nerve activity.
The study consists of three separate and consecutive periods:
- Baseline, a 20-minute period during which GES is left ON at each patient's pre-study settings;
- Experimental, a 4-hour period during which the GES device is turned OFF for participants in the experimental group;
- Recovery, a 20-minute period during which GES is turned back ON to the patient's pre-study settings for participants in the experimental group.
A 5-ml sample of blood will be collected from each patient after placement of the flexible IV catheter secured with tape, and after the Baseline, and Recovery study periods. During the Experimental period a blood sample is withdrawn after 30 minutes and then again at the 1-hour, 2-hour, 3-hour and 4-hour intervals through a flexible IV catheter secured with tape, with the possibility of up to 8 blood draws over the duration of the study. EKG and vagal nerve activity will be recorded continuously through the 3 study periods.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Thomas V Nowak, MD
- Numéro de téléphone: 3179484272
- E-mail: tvnowak@iu.edu
Sauvegarde des contacts de l'étude
- Nom: Maureen V Schilling, BS
- Numéro de téléphone: 3172782064
- E-mail: maschi@iu.edu
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University Hospital
-
Chercheur principal:
- Thomas V Nowak, MD
-
Contact:
- Maureen V Schilling, BS
- Numéro de téléphone: 3172782064
- E-mail: maschi@iu.edu
-
Contact:
- Thomas V Nowak, MD
- Numéro de téléphone: 317-948-4272
- E-mail: tvnowak@iu.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- At least 18 years of age.
- Documented diagnosis of gastroparesis
- Not taking diabetic prescribed exogenous insulin.
- Patient has a GES device that has been implanted for at least 3 months.
- Willing to give up to 8 blood samples.
- Willing to lie in a bed for up to 5.5 hours.
Exclusion Criteria:
- Pregnancy
- History of allergic reaction to EKG lead placement adhesives.
- Unable to give informed consent.
- Unwilling to give up to 8 5 ml blood samples.
- Unwilling to lie in a bed for up to 5.5 hours.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: The OFF Group
This group of subjects will have their GES interrogated and observed as well as having the device turned off for the duration of the experiment. The device will then be re-interrogated and turned back on at the end of the experiment. |
Device will either be turned off for the duration of the experimental period.
Autres noms:
|
|
Aucune intervention: Control Group
This group of subjects will undergo the same procedures as the experimental group, except that their GES will not be turned off during the experimental period. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in serum insulin
Délai: Day 1
|
To define the effect of prolonged four-hour withdrawal of gastric electrical stimulation on serum insulin. |
Day 1
|
|
Change in serum C-peptide
Délai: Day 1
|
To define the effect of prolonged four-hour withdrawal of gastric in human subjects. Insulin and C-peptide are co-primary end points. |
Day 1
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Changes in serum glucose
Délai: Day 1
|
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation. |
Day 1
|
|
Changes in serum GLP-1
Délai: Day 1
|
To compare the changes in serum GLP-1 and glucose levels after 4-hour withdrawal of gastric electrical stimulation to a control group that does not undergo withdrawal of gastric electrical stimulation. |
Day 1
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Thomas V Nowak, MD, IU School of Medicine/IU Health
Publications et liens utiles
Publications générales
- van der Voort IR, Becker JC, Dietl KH, Konturek JW, Domschke W, Pohle T. Gastric electrical stimulation results in improved metabolic control in diabetic patients suffering from gastroparesis. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):38-42. doi: 10.1055/s-2004-830525.
- Vosseler A, Zhao D, Fritsche L, Lehmann R, Kantartzis K, Small DM, Peter A, Haring HU, Birkenfeld AL, Fritsche A, Wagner R, Preissl H, Kullmann S, Heni M. No modulation of postprandial metabolism by transcutaneous auricular vagus nerve stimulation: a cross-over study in 15 healthy men. Sci Rep. 2020 Nov 24;10(1):20466. doi: 10.1038/s41598-020-77430-2.
- Kozorosky EM, Lee CH, Lee JG, Nunez Martinez V, Padayachee LE, Stauss HM. Transcutaneous auricular vagus nerve stimulation augments postprandial inhibition of ghrelin. Physiol Rep. 2022 Apr;10(8):e15253. doi: 10.14814/phy2.15253.
- Payne SC, Ward G, Fallon JB, Hyakumura T, Prins JB, Andrikopoulos S, MacIsaac RJ, Villalobos J. Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol Rep. 2022 Apr;10(8):e15257. doi: 10.14814/phy2.15257.
- Hampton RF, Jimenez-Gonzalez M, Stanley SA. Unravelling innervation of pancreatic islets. Diabetologia. 2022 Jul;65(7):1069-1084. doi: 10.1007/s00125-022-05691-9. Epub 2022 Mar 29.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 30020
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .